



IDS/ #7  
6/22/02  
Patent  
270/070

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: ) Group Art Unit: Not Yet Assigned  
John Langenfeld ) Examiner: Not Yet Assigned  
Serial No.: 10/044,716 )  
Filed: January 11, 2000 )  
For: BONE MORPHOGENETIC PROTEIN- )  
2 IN THE TREATMENT AND DIAGNOSIS )  
OF CANCER )

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution  
OC-112005.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

06/21/02

Lena Dishakjian  
Name of Person Mailing Paper  
Lena Dishakjian  
Signature of Person Mailing Paper-0

application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

- However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.
- However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.
- This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.
  - The fee due under 37 CFR § 1.17(p) is submitted herewith.
  - A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
- This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

**STATEMENT UNDER 37 CFR § 1.97(e):**

- Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**


- A check in the amount of \_\_\_\_\_ is enclosed for the above fee(s).
- Please charge \_\_\_\_\_ to Deposit Account No. 12-2475 for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,

LYON & LYON LLP

By:

  
Michael J. Wise  
Reg. No. 34,047

Dated: 6/18/02



22249

LYON & LYON  
LLP  
633, W. Fifth Street,  
Suite 4700  
Los Angeles, CA  
90071

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

OIS

JUN 25 2002

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

84

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

100

25 2002 <sup>4</sup> (use as many sheets as necessary)

Sheet 5

12

of 2

**Complete if Known**

Application Number 10/044,716

Application Number 10/044,719  
Filing Date January 14, 2002

Filing Date January 11, 2002

First Named Inventor John Langenfeld

Group Art Unit | Not Yet Assigned

Examiner Name Not Yet Assigned

Attorney Docket Number 270/070

#### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.